Advances in clinical treatment and biological features of primary plasma cell leukemia
10.3760/cma.j.issn.1009-9921.2018.07.016
- VernacularTitle:原发性浆细胞白血病的临床及生物学进展
- Author:
Tengteng YU
1
;
Gang AN
;
Yan XU
;
Lugui QIU
Author Information
1. 中国医学科学院北京协和医学院血液学研究所血液病医院血液学重点实验室
- Keywords:
Leukemia,plasma cell;
Multiple myeloma;
Hematopoietic stem cell transplantation;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2018;27(7):434-437
- CountryChina
- Language:Chinese
-
Abstract:
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell disorder with distinct clinical and biological features.Thanks to the application of novel agents such as proteasome inhibitors (e.g.bortezomib) and immunomodulatory drugs (e.g.thalidomide and lenalidomide),along with stem cell transplantation,the outcome of pPCL has been improved a lot.Despite therapeutic advances,the current understanding of pPCL biology is still limited due to the lack of availability of clinical samples.This review provides the recent progress of the diagnostic and therapeutic options in pPCL.
